Ireland's Endo International entered a definitive agreement with Auxilium Pharmaceuticals to acquire all of its outstanding shares of common stock for $2.6bn.
The company will make the purchase at the rate of $33.25 per share in a cash and stock transaction, which has been unanimously approved by the boards of directors of both companies.
As a result of the acquisition, Endo's pharmaceutical portfolio will have a broader offering of urology and orthopedic products that are natural complements to its men's health and pain products. The company also aims to achieve annual cost synergies of $175m.
US-based pharmaceuticals and health care products firm Abbott entered into an agreement to acquire medical device firm Topera, for $250m.
Topera is focused on developing new electrophysiology technologies to improve the diagnosis and treatment of atrial fibrillation, one of the most common heart rhythm disorders in the world.
Potential future payments based on achieving performance milestones are also included in the agreement, and the acquisition will allow Abbott to enter into the $3bn worth catheter-based electrophysiology market.
GE Healthcare subsidiary Clarient Diagnostic Services entered into a partnership with GlaxoSmithKline (GSK) to improve access to diagnostic testing for cancer patients.
Under the deal, a network of clinical laboratories will be established to identify genetic mutations associated with different tumour types, and will be made available as a subscription-based service.
The deal will allow GE to develop a broader laboratory and data analytics service that will enable better efficiency in the healthcare market related to oncology precision medicine.
IBM launched several humanitarian initiatives in Sierra Leone, as part of the fight against the deadly disease Ebola in West Africa.
In collaboration with Sierra Leone's Open Government Initiative, IBM's new research lab in Africa developed an engagement and analytics system, allowing citizens to report Ebola-related issues via SMS or voice calls directly to the government, health agencies and others to keep track of the disease.
The system provides insight for the government about the day-to-day experiences of communities directly affected by Ebola to help improve its strategy for containing the disease.
US-based Unilife signed a worldwide master services and commercial supply agreement with French drug-maker Sanofi for wearable injectors.
Under the 15-year deal, Unilife will supply cartridge-based wearable injectors for all of Sanofi's applicable large dose volume drugs, excluding insulins.
The deal will also allow Sanofi to make Unilife's wearable injectors available to its partners for use with applicable molecules under joint collaborations.
Japan-based Panasonic launched three new products, as part of its age-free solution, at the 41st Home Care and Rehabilitation Exhibition in Tokyo.
Products introduced by the company include Resyone, an electric care bed with a section that can be separated and transformed into a fully reclining electric wheelchair to help users get out of bed.
The company also introduced a self-reliance support robot that allows users to stand-up, walk and sit down.
In addition, the company showcased Digital Mirror, a rehabilitation navigation system for hospitals and facilities, as well as Aqua Heart J Series (prototype), a barrier-free bath unit that was developed to help users be as independent as possible, while taking a bath.
Carl Zeiss Meditec, a German medical technology firm, introduced a new Zeiss cataract suite, which will provide physicians with placement of incisions, the centration of intraocular lens (IOLs), and alignment of toric IOLs along the optimal target axis.
The markerless alignment supports the toric IOL implantation using a combination of technologies. These include: IOLMaster 500 optical biometer, OPMI lumera surgical microscopes, Callisto eye computer-assisted cataract surgery system and the forum data management system.
The company said the FDA 510(k) cleared markerless version prevents the step of pre-operative marking of the corneal surface of the patient's eye.
The Frankfurt University Hospital in Germany used US-based Aethlon Medical's Hemopurifier therapy for the first time to treat a patient infected with the Ebola virus.
The treatment was administered to a Ugandan doctor who is also a World Health Organization (WHO) worker, after contracting the virus while working in Sierra Leone.
Hemopurifier is a first-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals.